VANDA PHARMACEUTICALS INC
NASDAQ: VNDA (Vanda Pharmaceuticals Inc.)
最近更新时间: 16分钟之前3.88
0.09 (2.37%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Vanda Pharmaceuticals Inc. | 混合的 | 看涨 |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | NA |
| 价格波动 | 2.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -2.5 |
| 相对估值 | NA |
| 财务健康 | 0.0 |
| 宏观环境 | -2.8 |
| AI Insight | NA |
| AI Technical | NA |
| 平均 | -0.51 |
|
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Value |
| 内部持股比例 | 7.16% |
| 机构持股比例 | 78.96% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Renaissance Technologies Llc | 30 Jun 2026 | 3,441,361 |
| Aigh Capital Management Llc | 30 Sep 2026 | 2,250,000 |
| Acadian Asset Management Llc | 30 Jun 2026 | 1,918,063 |
| Two Sigma Investments, Lp | 30 Jun 2026 | 1,349,072 |
| Jacobs Levy Equity Management, Inc | 30 Jun 2026 | 1,213,326 |
| Krensavage Asset Management, Llc | 30 Jun 2026 | 1,180,388 |
该时间范围内无数据。
投资组合